CTI Clinical Trial and Consulting Services, a global, privately owned, full-service contract research organization, expands its presence with the opening of a new campus near downtown Cincinnati, Ohio. The project is expected to create 70 new jobs.
The company will occupy 37,000 square feet of the Baldwin 500 building. The room will house CTI’s new Laboratory Services business unit in North America, a first step in a global expansion. The business unit will provide molecular, cellular and bioanalytical tests as well as biorepository and kit building services to the company’s customers.
“As we continue to expand our presence in the tri-state on both sides of the river, we hope to become a model for other companies,” added Tim Schroeder, Chairman & CEO of CTI. “Our region is incredibly rich in talent, capable, trained professionals who save lives every day, skills that we have proven time and again in the fight against COVID-19. We hope that our continued success will encourage others to consider creating jobs in the area. Thanks to JobsOhio, REDI Cincinnati, the State of Ohio, the City of Cincinnati, Corporex, Gravity Diagnostic, and countless other companies for helping us make this point. “
The new campus is less than 10 minutes from CTI Global Headquarters and the CTI Clinical Research Center in Norwood.
In support of the project, the company will receive a job creation tax credit and additional incentives from the City of Cincinnati from the Ohio Development Services Agency. JobsOhio plans to provide support for the project, which will be released after a definitive agreement is reached. Cincinnati City Local Incentives are yet to be approved.
“The Cincinnati area stands out as a leader in the organic health industry thanks to the investment by CTI and the more than 800 organic health companies that call the region home,” said Kimm Lauterbach, President and CEO of REDI Cincinnati. “The expansion of CTI to include laboratory services is a testament to the region’s continued dynamism in this area. Support from the City of Cincinnati, JobsOhio, and the Ohio Development Services Agency made this project a success. “
CTI is currently part of 40 active COVID-19 diagnosis, treatment and prevention projects, including work on Janssen’s COVID-19 vaccine. CTI is now in its third decade one of the 20 largest CROs in the world, with employees in more than 60 countries on six continents.
“CTI is an innovative local company bringing top talent to our urban core,” noted Markiea L. Carter, interim director, Cincinnati City Community and Economic Development Department. “You have made such a significant impact on biotechnology and medicine around the world and we are delighted to welcome you to your new facility.”
Comments are closed.